Mather Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.5K Sell
206
-570
-73% -$90K ﹤0.01% 1290
2026
Q2
$123K Sell
776
-160
-17% -$21.6K ﹤0.01% 892
2026
Q1
$120K Buy
+936
New +$117K ﹤0.01% 852
2025
Q4
– Sell
-46
Closed -$4.61K – 1664
2025
Q3
$4.61K Buy
+46
New +$4.14K ﹤0.01% 1407
2025
Q2
– Sell
-48
Closed -$3.89K – 1743
2025
Q1
$3.89K Hold
48
– – ﹤0.01% 1449
2024
Q4
$4.32K Hold
48
– – ﹤0.01% 1402
2024
Q3
$4.74K Sell
48
-827
-95% -$81.3K ﹤0.01% 1308
2024
Q2
$83K Buy
875
+827
+1,723% +$74.1K ﹤0.01% 859
2024
Q1
$4.29K Buy
+48
New +$4.45K ﹤0.01% 1378
2014
Q2
– Sell
-193,710
Closed -$9.2M – 25
2014
Q1
$9.2M Sell
193,710
-38,562
-17% -$1.97M 3.37% 13
2013
Q4
$10.1M Buy
232,272
+3,801
+2% +$157K 3.84% 11
2013
Q3
$9.8M Sell
228,471
-2,940
-1% -$119K 4.08% 10
2013
Q2
$8.04M Buy
+231,411
New +$8.13M 3.47% 12

Other funds holding XBI

Mather Group's XBI Position: Q3 2026 in Review

Mather Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 73% in Q3 2026, selling an estimated $90K and leaving 206 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Mather Group first reported a position in XBI in Q2 2013 and has held it in 13 quarters since. The position peaked at $10.1M in Q4 2013. 235 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Mather Group held 206 shares of State Street SPDR S&P Biotech ETF worth $32.5K as of Q3 2026.
  • Mather Group sold 570 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $90K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1290 holding.
  • Mather Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 13 quarters since.
  • Mather Group's State Street SPDR S&P Biotech ETF position peaked at $10.1M in Q4 2013.
  • 235 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.